These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 940883)

  • 1. [Usefulness for differential diagnosis of the distribution of extrapyramidal symptoms resulting from neuroleptic therapy in psychiatric practice].
    Bódog G
    Psychiatr Neurol Med Psychol (Leipz); 1976 Jan; 28(1):51-7. PubMed ID: 940883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroleptic induced extrapyramidal symptoms.
    Donlon PT; Stenson RL
    Dis Nerv Syst; 1976 Nov; 37(11):629-35. PubMed ID: 136337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of neuroleptic withdrawal on the drug-induced extrapyramidal syndrome of chronic schizophrenia].
    Elie R; Gagnon MA; Gauthier R; Jéquier JC
    Union Med Can; 1975 Jun; 104(6):909-14. PubMed ID: 772906
    [No Abstract]   [Full Text] [Related]  

  • 4. Dexetimide (R 16470) in the control of neuroleptic-induced extrapyramidal side-effects. Its prophylactic value and duration of action.
    Huygens H; Vereecken JL; Tanghe A
    Psychiatr Neurol Neurochir; 1973; 76(4):251-9. PubMed ID: 4581374
    [No Abstract]   [Full Text] [Related]  

  • 5. [Extrapyramidal symptoms following Clozapine therapy. Case report].
    Doepp S; Buddeberg C
    Nervenarzt; 1975 Oct; 46(10):589-90. PubMed ID: 811999
    [No Abstract]   [Full Text] [Related]  

  • 6. The purely neuroleptic effects and its relation to the "neuroleptic threshold".
    Haase HJ
    Acta Psychiatr Belg; 1978; 78(1):19-36. PubMed ID: 645405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The schizophrenias: medical diagnosis and treatment by the family physician.
    Donlon PT
    J Fam Pract; 1978 Jun; 6(1):71-82. PubMed ID: 621484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catatonic variants, hyperthermic extrapyramidal reactions, and subtypes of neuroleptic malignant syndrome.
    Lee JW
    Ann Clin Psychiatry; 2007; 19(1):9-16. PubMed ID: 17453656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of neuroleptic dosage and extrapyramidal side effects on schizophrenic basic symptoms.
    Moritz S; Krausz M; Gottwalz E; Andresen B
    Compr Psychiatry; 2000; 41(4):284-8. PubMed ID: 10929797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
    Nasrallah HA; Brecher M; Paulsson B
    Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinematical analysis of motor function in schizophrenic patients: a possibility to separate negative symptoms from extrapyramidal dysfunction induced by neuroleptics?
    Henkel V; Mergl R; Schäfer M; Rujescu D; Möller HJ; Hegerl U
    Pharmacopsychiatry; 2004 May; 37(3):110-8. PubMed ID: 15138894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical evaluation of amantadine in the treatment of extrapyramidal syndromes caused by neuroleptic drugs].
    Bukowczyk A; Wasik A; Horodnicki J
    Psychiatr Pol; 1974; 8(2):143-8. PubMed ID: 4830321
    [No Abstract]   [Full Text] [Related]  

  • 13. Antiparkinson medication in the treatment of extrapyramidal side effects: single of multiple daily doses?
    Neu C; Dimascio A; Demirgian E
    Curr Ther Res Clin Exp; 1972 May; 14(5):246-51. PubMed ID: 4623975
    [No Abstract]   [Full Text] [Related]  

  • 14. [Present-day possibilities of relieving post-neuroleptic extrapyramidal symptoms].
    Wasik A
    Psychiatr Pol; 1973; 7(1):51-6. PubMed ID: 4715833
    [No Abstract]   [Full Text] [Related]  

  • 15. [A chronic extrapyramidal syndrome as a complication of neuroleptic therapy].
    Gurovich IIa; Fleĭs EP
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1969; 69(12):1862-8. PubMed ID: 5375563
    [No Abstract]   [Full Text] [Related]  

  • 16. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects.
    Kinon BJ; Kane JM; Chakos M; Munne R
    Psychopharmacol Bull; 1993; 29(3):365-9. PubMed ID: 7907184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The extrapyramidal neuroleptic syndrome: description and measurement.
    Elie R; Gagnon MA; Lamontagne Y; Tetreault L
    Curr Ther Res Clin Exp; 1973 Jul; 15(7):427-40. PubMed ID: 4198304
    [No Abstract]   [Full Text] [Related]  

  • 18. Bipolar course in schizo-affective illness.
    Sovner RD; McHugh PR
    Biol Psychiatry; 1976 Apr; 11(2):195-204. PubMed ID: 971445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant neuroleptic syndrome--its present status in Japan and clinical problems.
    Itoh H; Ohtsuka N; Ogita K; Yagi G; Miura S; Koga Y
    Folia Psychiatr Neurol Jpn; 1977; 31(4):559-76. PubMed ID: 608659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open study with bromperidol (C-C 2489), a new neuroleptic, for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.
    Haase HJ; Kaumeier S; Schwarz H; Gundel A; Linde OK; Maetz H; Scheel R; Stripf A; Stripf L
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Mar; 11(2):81-5. PubMed ID: 643910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.